【摘要】 目的研究常规溶栓联合氯吡格雷治疗急性ST段抬高心肌梗死患者的疗效和安全性。方法随机选择2005年1月至2007年12月于栾川县人民医院住院的急性ST段抬高心肌梗死发病6h以内患者90例,其中联合氯吡格雷治疗者(氯吡格雷组)48例,未联合氯吡格雷者(对照组)42例。观察两组主要疗效和安全性指标。结果氯吡格雷组较对照组具有较高的血管再通率(分别为68.8%、50.0%,P<0.05),主要不良心脏事件发生率降低(分别为4.2%、14.3%,P<0.05),出血发生率与对照组比较差异无统计学意义(分别为8.3%、9.5%,P>0.05)。结论溶栓联合氯吡格雷治疗急性ST段抬高心肌梗死患者是安全有效的。更多还原

【Abstract】 Objective To observe the efficacy and safety of addition of clopidogrel to fibrinolytic therapy for acute ST-segment elevation myocardial infarction. Methods Patients underwent acute ST-segment elevation myocardial infarction within 6 hours were recruited in the people’s hospital of luanchuan county from January 2005 to December 2007. Patients (n=90) were allocated into 2 groups,one group received clopidogrel (n=48),the other group didn’t receive clopidogrel (n=42). The main indicators of efficacy and safety were observed. Results The patency of infarct-related artery rate was significantly higher in the clopidogrel group than that in the control group (68.8% vs 50.0%,P<0.05). The major adverse cardiac events rates were significantly lower than those in the control group(4.2% vs 14.3%,P<0.05). The rate of hemorrhage events did not differ significantly between the two groups (8.3% vs 9.5%,P>0.05). Conclusion Addition of clopidogrel to fibrinolytic therapy is safe and effective for the ST-segment elevation myocardial infarction patients.更多还原